Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing
Brief intro:
- Author: Xiangfeng Kong, Hainan Zhang, Guoling Li, Zikang Wang, Xuqiang Kong, Lecong Wang, Mingxing Xue, Weihong Zhang, Yao Wang, Jiajia Lin, Jingxing Zhou, Xiaowen Shen, Yinghui Wei, Na Zhong, Weiya Bai, Yuan Yuan, Linyu Shi, Yingsi Zhou, and Hui Yang
- Journal: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-023-37829-7
- Publication Date: 2023 Apr 11
Products/Services used in the paper
Quotation shows PackGene:Circ-arRNAs were packaged in AAV8 by PackGene Biotech.
Research Field:RNA editing
AAV Serotype:AAV8
Animal or cell line strain:The experimental animals included 4- or 6-week-old Idua-W392X (B6.129S-Iduatm1.1Kmke/J) female mice (Jackson Laboratory, no. 017681) and C57BL/6 J female mice (Beijing Vital River Laboratory).
Abstract
The type V-F CRISPR-Cas12f system is a strong candidate for therapeutic applications due to the compact size of the Cas12f proteins. In this work, we identify six uncharacterized Cas12f1 proteins with nuclease activity in mammalian cells from assembled bacterial genomes. Among them, OsCas12f1 (433 aa) from Oscillibacter sp. and RhCas12f1 (415 aa) from Ruminiclostridium herbifermentans, which respectively target 5' T-rich Protospacer Adjacent Motifs (PAMs) and 5' C-rich PAMs, show the highest editing activity. Through protein and sgRNA engineering, we generate enhanced OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants, with 5'-TTN and 5'-CCD (D = not C) PAMs respectively, exhibiting much higher editing efficiency and broader PAMs, compared with the engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1). Furthermore, by fusing the destabilized domain with enOsCas12f1, we generate inducible-enOsCas12f1 and demonstate its activity in vivo by single adeno-associated virus delivery. Finally, dead enOsCas12f1-based epigenetic editing and gene activation can also be achieved in mammalian cells. This study thus provides compact gene editing tools for basic research with remarkable promise for therapeutic applications.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
